Almost half of teens and young adults with acute myeloid leukaemia (AML) – a typically aggressive form of leukaemia – are cured thanks to improvements in treatment and care, according to research published in the British ...
Jun 24, 2013
0
0
A protein – already known to be involved in a cell's response to stress – called Tetratricopeptide repeat domain 5 (TTC5) is critical to the development of acute myeloid leukaemia (AML), according to a new Cancer Research ...
Apr 5, 2013
0
0
University of New South Wales researchers have developed a compound that has had a surprise result: being effective in the prevention of asthma.
Jan 22, 2013
1
0
Survival for people diagnosed with Chronic Myeloid Leukaemia (CML) has risen by nearly half, with around 58 per cent of people surviving their disease for at least five years compared with only around 40 per cent in the late ...
Dec 12, 2012
0
0
Early results of a trial to treat leukaemia with a WT1 DNA vaccine, has shown robust vaccine-specific antibody responses in all vaccinated patients evaluated to date.
Dec 7, 2012
0
0
Many observational epidemiologic studies have found an inverse association between alcohol consumption and hematological cancers (such as lymphoma and leukemia). This study, based on the Million Women's Study in the UK, is ...
Nov 13, 2012
0
0
(Medical Xpress)—Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their ...
Nov 12, 2012
0
0
Leading scientists in the field investigated the potential of RNA interference (RNAi) technology as a therapeutic intervention for down-regulating the expression of disease-associated genes. Project deliverables hold significant ...
Sep 20, 2012
0
0
(Medical Xpress) -- Scientists in a team at Newcastle University have identified a mechanism by which treatment-related leukaemia develops, raising hopes that this side effect of toxic chemotherapy could be prevented.
May 31, 2012
0
0
Using fractionated doses of the targeted anticancer drug gemtuzumab ozogamicin allows for safer delivery of the drug into patients aged 50-70 years with acute myeloid leukaemia (AML) and substantially improves their outcomes. ...
Apr 4, 2012
0
0
